pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Iluvien
drug
save

fluocinolone acetonide SR

Marketedupdated 3mo ago
by Alimera Sciences Inc
Approved
community read0 votes

🐶 often sniffed alongside

top 6
  • tagApproval8 co-mentions · 4 sources
  • drugfluocinolone acetonide ER5 co-mentions · 5 sources
  • drugfluocinolone acetonide5 co-mentions · 5 sources
  • drugRetisert5 co-mentions · 5 sources
  • companySun Pharmaceutical Industries Ltd1 co-mentions · 1 sources
  • tagRecall1 co-mentions · 1 sources

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 11 approved and 6 investigational indications.

indications

investigational
Diabetic Macular Edema

all catalysts(0)

nothing on the calendar yet

Trials studying fluocinolone acetonide SR

  • phase3Intravitreal Faricimab Injections or Fluocinolone Acetonide (0.19 mg) Intravitreal Implants vs Observation for Prevention of VA Loss Due to Radiation Retinopathyrecruitingn=600
  • phase4Fluocinolone Acetonide Intravitreal Implant 0.18 mg in the Treatment of Chronic Non-Infectious Posterior Segment Uveitisactive not recruitingn=125
  • phase4Open Label Trial Studying the Safety and Effectiveness of ILUVIEN® (190μg) in Children and Adolescents, Who Have Recurrent Non-infectious Uveitis Affecting the Posterior Segment of the Eye.recruitingn=25
  • phase4A Study of Intravitreal ILUVIEN® Implant as Baseline Therapy in Patients With Early Diabetic Macular Edema (DME)active not recruitingn=300

Patent cliff

source: FDA Orange Book
first barrier falls
Aug 12, 2027
356 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (4)

  • Nov 7, 2028formulationUS 98490272.2y
  • Jan 12, 2028formulationUS 79981081.4y
  • Aug 12, 2027formulationUS 8871241356d
  • Aug 12, 2027formulationUS 8871241356d

News(0)

no news has mentioned this drug yet

brand
Iluvien
generic
fluocinolone acetonide
MOA
Glucocorticoid receptor agonist
indication
Diabetic Macular Edema
phase
marketed
Data sources
ClinicalTrials.gov
last refreshed 53m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?